R&D Bioanalytical labs need to reimagine data to streamline thei... The fundamental questions in the trial phases of drug development are “Does it work?”, “Is it safe?”, and “What else do we need to know?”
News NICE backs first targeted therapy for ALK+ lung cancer Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.
Sales & Marketing Sponsored Global reach, personal touch: Mastering customer engagement ... In today's interconnected pharma market, the ability to scale engagement across borders is essential for survival and growth.